Sunday, July 31, 2022
12:45 PM - 2:00 PM PT`
San Diego, CA
Marriott Marquis San Diego Marina
San Diego, California
Alireza Atri, MD, PhD
Director, Banner Sun Health Research Institute
Memory and Cognitive Disorders, Neurology
Sun City, Arizona
Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada
Marwan N. Sabbagh, MD, FAAN
Professor of Neurology, Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
Research Professor, University of Arizona College of Medicine-Phoenix
Clinical Professor of Neurology, Creighton University
Lunch/Registration: 12:30 pm-12:45 pm PT
Educational Session: 12:45 pm-2:00 pm PT
Lunch will be provided.
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Biogen MA, Inc.
A CME Corporate Sponsored Symposium held in conjunction with the Alzheimer’s Association International Conference.
This activity is designed to educate a multidisciplinary audience, including neurologists, geriatricians, and other clinicians involved in the management of patients with mild cognitive impairment (MCI) or early-stage Alzheimer’s disease (AD).
Alzheimer’s disease is becoming increasingly prevalent as the general population ages and is expected to affect 14 million people by 2050. As research continues to evolve, new understanding of pathophysiological targets has shaped drug development, leading to the recent approval of an anti-amyloid therapy, with hope that additional targeted therapies will follow. Clinicians must incorporate not only traditional means of assessing cognitive decline in practice, but also advances in biomarker techniques and novel therapies. Faculty will discuss and debate topics related to the pathophysiology of Alzheimer’s disease including implications for treatment targets, best practices for assessing patients with MCI or early-stage disease, the latest clinical profiles and trial evidence for newer targeted therapies, and how to best utilize these treatment options in real-world practice.
Upon completion of this activity, the participant should be better able to:
- Describe clinically relevant aspects of Alzheimer’s disease pathophysiology, including amyloid β and tau
- Evaluate patients with mild cognitive impairment or Alzheimer’s disease using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews
- Explain clinical trial data, challenges, and future directions with targeted therapies for early Alzheimer’s disease
- Manage patients with early-stage Alzheimer’s disease through ongoing communication, shared decision making, and appropriate selection for treatment with targeted therapy
12:30 PM - 12:45 PM Registration
12:45 PM – 12:50 PM Preactivity Questionnaire and Faculty Instructions
12:50 PM – 1:05 PM What's the latest on Alzheimer's Disease Pathophysiology?
1:05 PM – 1:25 PM Evaluating Patients With MCI or Early-Stage Alzheimer's Disease
1:25 PM – 1:45 PM New Treatment Strategies for Early-Stage Disease
1:45 PM – 2:00 PM Postactivity Questionnaire and Q&A Session
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s)
*Pharmacology hours to be determined during clinical content review.
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Julie Krauss prior to the live event at email@example.com
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.